Media headlines about Cellectar Biosciences (NASDAQ:CLRB) have trended positive on Saturday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectar Biosciences earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.2175574040033 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
CLRB has been the topic of a number of research reports. Zacks Investment Research downgraded Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. ValuEngine raised Cellectar Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday.
Cellectar Biosciences (NASDAQ CLRB) traded down $0.03 during mid-day trading on Friday, reaching $1.14. The company had a trading volume of 137,616 shares, compared to its average volume of 337,588. Cellectar Biosciences has a fifty-two week low of $1.06 and a fifty-two week high of $3.07. The firm has a market cap of $18.50, a P/E ratio of -1.07 and a beta of 0.85.
Cellectar Biosciences (NASDAQ:CLRB) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). equities analysts predict that Cellectar Biosciences will post -0.96 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/03/positive-press-coverage-somewhat-unlikely-to-impact-cellectar-biosciences-clrb-stock-price.html.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.